Vaxcyte FY23 net loss $402M; VAX-31 adult Phase 1/2 topline data Q3 2024; cash $1.24B

Vaxcyte, Inc.

2023-FY EPS reported -$4.14

Net loss of $402.3M for FY2023 (vs $223.5M in FY2022); cash, equivalents & investments $1.24B as of Dec 31, 2023.
VAX-31 adult Phase 1/2 study enrollment complete; topline safety, tolerability & immunogenicity data expected Q3 2024.
VAX-24 adult program Phase 3-ready following End-of-Phase 2 FDA meeting; either VAX-24 or VAX-31 to advance after VAX-31 readout.
VAX-24 infant Phase 2 enrollment nearing completion; topline data from primary series by end Q1 2025, booster by end 2025.
R&D expenses $332.3M for FY2023, up 96% YoY due to manufacturing scale-up for PCV programs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxcyte, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-021081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.